Monday, September 11, 2017

Comparison of Serum Lipid Profile Changes during Treatment of Olanzapine and Risperidone


Amita Gupta1*, Aashish Jadhav2, Vaibhav Dubey3
1Reader & HOD, Department of Biochemistry, Mansarovar Dental College, Kolar Road, Bhopal, (MP), India
2Professor & Head, Department of Biochemistry, BKL Walawalkar Rural Medical College, Sawarde, Ratnagiri (Maharashtra), India   
3Associate Professor, Department of Psychiatry, People’s College of Medical Sciences and Research Centre, Bypass Road, Bhanpur, Bhopal (MP), India
 *Address for Correspondence: Dr. Amita Gupta, Reader & HOD, Department of Biochemistry, Mansarovar Dental College, Kolar Road, Bhopal, MP, India
ABSTRACT- Background: Several studies demonstrated relationship between dyslipidemia and various antipsychotic drugs after treatment of psychotic disorders. Our study aimed to compare the effects of commonly prescribed antipsychotic drugs Risperidone and Olanzapine on serum lipid profile of psychiatric patients.
Materials and Methods: This current study was conducted on 30 psychiatric patients, divided in to two groups according to the antipsychotic drug prescribed by doctor Risperidone or Olanzapine. All the patients were assessed for changes in serum lipid profile Total cholesterol (TC), Triglycerides (TG), High Density Lipoprotein (HDL-C), Low Density Lipoprotein (LDL-C), Very Low Density Lipoprotein (VLDL-C) & Risk Factors for coronary artery disease (CAD Risk Factor I &II) after 16 weeks of treatment.
Results: Patients taking Olanzapine therapy were showed significant (p<0.05) increase in all lipid parameters, whereas Risperidone treated patients were showed significant increase in serum triglyceride and VLDL-C only.
Conclusion: Olanzapine therapy is strongly associated with dyslipidemia than Risperidone.

Key-words- Dyslipidemia, Lipid profile, Coronary artery disease, Risk factors, Schizophrenia